Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 20Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 43Myeloid 12Other hematologic neoplasm 8Lymphoid 5Gynecologic 4Thoracic 3Plasma cell 3Genitourinary 3Breast 2Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 478Neoplasms, Plasma Cell 102Lymphoma 86Lymphoma, Non-Hodgkin 75Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 71Recurrence 68Leukemia, Myeloid, Acute 68Leukemia 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Hodgkin Disease 66Lymphoma, Mantle-Cell 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Follicular 45Myeloproliferative Disorders 43Neoplasms 41Lymphoma, B-Cell, Marginal Zone 41Burkitt Lymphoma 41Primary Myelofibrosis 38Lymphoma, Large-Cell, Immunoblastic 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Myelomonocytic, Chronic 31Sezary Syndrome 29Mycosis Fungoides 29Leukemia, Myeloid, Chronic-Phase 29Leukemia, Myeloid, Accelerated Phase 29Congenital Abnormalities 29Leukemia, Hairy Cell 27Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25

Interventions

venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1bicalutamide 1abiraterone 1abemaciclib 1XRP6258 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Anemia × Plasma cell × Clear all
NCT04582539 2025-10-22

LIMBER

Incyte Corporation

Phase 1/2 Terminated
22 enrolled 28 charts
Classical hematologyMyeloidPlasma cell

Anemia, Multiple Myeloma, Myelodysplastic Syndromes

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03303950 2022-05-05

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

University of Utah

Phase 2 Terminated
6 enrolled 17 charts
Classical hematologyMyeloidPlasma cell

Anemia, Multiple Myeloma, Thrombocytopenia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡